ClinicalTrials.gg
CompletedNCT04398706Updated Sep 8, 2025Results posted

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

A Phase 2 interventional study of Pneumococcal Conjugate Vaccine formulation 1 and Pneumococcal Conjugate Vaccine formulation 2 in Pneumococcal Immunisation, Diphtheria Immunisation and Tetanus Immunisation, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 57 sites in 4 countries. Open to participants aged 42 Days to 15 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
852
Allocation
Randomized
Ages
42 Days to 15 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing Chickenpox Vaccine in Chickenpox — 5 open to participants now, 7 under way, 4 of them phase 3. Chickenpox Vaccine · Chickenpox.

Enrollment
9th of 36
852 · median 404
Started
2020
the only one that year
Phase 2
2 of 36
none open now
Registered
25th of 36
by date

Among the 36 studies testing Chickenpox Vaccine in Chickenpox, this one is the 9th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 2, and was the 25th registered.

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

Browse Chickenpox studies →

Open to participants now

5 of the 36 studies testing Chickenpox Vaccine in Chickenpox are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 42 Days to 15 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing Chickenpox Vaccine in Chickenpox, or all of them as a file.
02

Study summary

Primary objectives:

  • To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection).
  • To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1-4)
  • To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of 3 doses in infants (Groups 5-8)
  • To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after administration of a 4-dose schedule in infants (Groups 5-8)

Secondary objectives:

  • To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1-4)
  • To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and Prevnar 13 1 month after the administration of 3 doses in a subset of infants (Groups 5-8)
  • To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and Prevnar 13 1 month after administration of a 4-dose schedule in a subset of infants (Groups 5-8)
  • In toddlers: to describe the Ab responses against Pentacel antigens before and 1 month following injection of Pentacel
  • In infants: to describe the Ab responses against antigens of the routine pediatric vaccines (Pentacel, RotaTeq, ENGERIX-B, M-M-RII, and VARIVAX) when administered concomitantly with either SP0202 or Prevnar 13 (at pre-Dose 1 (as applicable) for RotaTeq, Diphteria, Tetanus and Pertussis antigens; at PD3 for ENGERIX-B, RotaTeq, and Pentacel; at PD4 for M-M-RII and VARIVAX])
Read the detailed description

For toddlers, the duration of each participant's participation in the study will be approximately 6 months for subjects enrolled in Groups 1, 2, 3, and 4.

For infants, the duration of each participant's participation in the study will be approximately 16 to 19 months for subjects enrolled in Groups 5, 6, 7, and 8.

03

Conditions studied

  • Pneumococcal Immunisation
  • Diphtheria Immunisation
  • Tetanus Immunisation
  • Pertussis Immunisation
  • Hepatitis B Immunisation
  • Haemophilus Influenzae Type b Immunisation
  • Polio Immunisation
  • Measles Immunisation
  • Rubella Immunisation
  • Varicella Immunisation
  • Mumps Immunisation
04

Who can participate

Ages eligible
42 Days to 15 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Toddlers and infants:

  • Participant and parent/guardian are able to attend all scheduled visits and to comply with all study procedures
  • Born at full term of pregnancy (≥ 37 weeks) and/or with a birth weight ≥ 5.5 lbs or 2.5 kg

Specifically for toddlers:

  • Aged 12 to 15 months on the day of the first study visit
  • Participant has received 3 doses of Prevnar 13 and 3 doses of diphteria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b antigens in infancy

Specifically for infants:

- Aged 42 to 89 days on the day of the first study visit

Exclusion criteria

Exclusion criteria:

Toddlers and infants

  • Participation at the time of study enrollment (or in the 4 weeks preceding the first study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
  • Family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated
  • Blood dyscrasias, leukemia, lymphoma of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems
  • Active tuberculosis
  • History of S. pneumoniae infection or disease, confirmed either serologically or microbiologically
  • History of any neurologic disorder, including any seizures and progressive neurologic disorders
  • History of Guillain-Barré syndrome
  • Known systemic to any of the vaccine components or to latex, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances
  • Verbal report of thrombocytopenia contraindicating intramuscular vaccination in the Investigator's opinion
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination in the Investigator's opinion
  • Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw
  • Chronic illness (including, but not limited to, cardiac disorders, congenital heart disease, chronic lung disease, renal disorders, auto-immune disorders, diabetes, psychomotor diseases, and know congenital or genetic diseases) that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion
  • Any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives
  • In an emergency setting, or hospitalized involuntarily
  • Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0 C / ≥ 100.4 F). A prospective participant should not be included in the study until the condition has resolved or until 3 days after the febrile event has resolved
  • Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study Specifically for toddlers
  • Receipt of any vaccine in the 4 weeks preceding the study vaccination or planned receipt of any vaccine from enrollment through the last blood sampling Visit (Visit 2), except for influenza vaccination, which may be received at least 2 weeks before or 2 weeks after any study vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • History of diphtheria, tetanus, pertussis, poliomyelitis, and/or H. influenzae type b infection or disease Specifically for infants
  • Receipt of any vaccine in the 4 weeks preceding the study vaccination or planned receipt of any vaccine from enrollment through the last blood sampling Visit (Visit 6), except for influenza vaccination or COVID-19 vaccination, which may be received at least 2 weeks before or 2 weeks after any study vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines, and COVID-19 vaccines as applicable per local recommendations
  • Receipt of immune globulins, blood or blood-derived products since birth.
  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks) since birth
  • Previous vaccination against S. pneumoniae
  • Previous vaccination against the following antigens: diphteria, tetanus, pertussis, H. influenzae type b, poliovirus, rotavirus, measles, mumps, rubella, and varicella
  • Receipt of more than 1 previous dose of vaccine
  • History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, measles, mumps, rubella, varicella, H. influenzae type b, and/or rotavirus infection or disease
  • History of intussusception

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
852 participants (actual)

Study arms

  • Experimental
    Group 1

    One dose of SP0202-IIb and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13

    Biological: Pneumococcal Conjugate Vaccine formulation 1 · Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)

  • Experimental
    Group 2

    One dose of SP0202-VI and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13

    Biological: Pneumococcal Conjugate Vaccine formulation 2 · Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)

  • Experimental
    Group 3

    One dose of SP0202-VII and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13

    Biological: Pneumococcal Conjugate Vaccine formulation 3 · Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)

  • Active comparator
    Group 4

    One dose of Prevnar 13 and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13

    Biological: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein] · Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)

  • Experimental
    Group 5

    Four doses of SP0202-IIb at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable

    Biological: Pneumococcal Conjugate Vaccine formulation 1 · Biological: Varicella Virus Vaccine Live · Biological: Measles, Mumps, and Rubella Virus Vaccine Live · Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) · Biological: Rotavirus Vaccine, Live, Oral, Pentavalent · Biological: Hepatitis B Vaccine* [Recombinant] *as applicable

  • Experimental
    Group 6

    Four doses of SP0202-VI at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable

    Biological: Pneumococcal Conjugate Vaccine formulation 2 · Biological: Varicella Virus Vaccine Live · Biological: Measles, Mumps, and Rubella Virus Vaccine Live · Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) · Biological: Rotavirus Vaccine, Live, Oral, Pentavalent · Biological: Hepatitis B Vaccine* [Recombinant] *as applicable

  • Experimental
    Group 7

    Four doses of SP0202-VII at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable

    Biological: Pneumococcal Conjugate Vaccine formulation 3 · Biological: Varicella Virus Vaccine Live · Biological: Measles, Mumps, and Rubella Virus Vaccine Live · Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) · Biological: Rotavirus Vaccine, Live, Oral, Pentavalent · Biological: Hepatitis B Vaccine* [Recombinant] *as applicable

  • Active comparator
    Group 8

    Four doses of Prevnar 13 at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable

    Biological: Varicella Virus Vaccine Live · Biological: Measles, Mumps, and Rubella Virus Vaccine Live · Biological: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein] · Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) · Biological: Rotavirus Vaccine, Live, Oral, Pentavalent · Biological: Hepatitis B Vaccine* [Recombinant] *as applicable

Interventions

  • BiologicalPneumococcal Conjugate Vaccine formulation 1

    Pharmaceutical form:liquid Route of administration: intramuscular

    Also known as: SP0202-IIb

  • BiologicalPneumococcal Conjugate Vaccine formulation 2

    Pharmaceutical form:liquid Route of administration: intramuscular

    Also known as: SP0202-VI

  • BiologicalPneumococcal Conjugate Vaccine formulation 3

    Pharmaceutical form:liquid Route of administration: intramuscular

    Also known as: SP0202-VII

  • Pharmaceutical form:liquid Route of administration: subcutaneous

    Also known as: Varicella vaccine, VARIVAX®

  • BiologicalMeasles, Mumps, and Rubella Virus Vaccine Live

    Pharmaceutical form:liquid Route of administration: subcutaneous

    Also known as: MMR vaccine, M-M-R ®II

  • Pharmaceutical form:liquid Route of administration: intramuscular

    Also known as: Prevnar 13®

  • BiologicalDiphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)

    Pharmaceutical form:liquid Route of administration: intramuscular

    Also known as: DTaP-IPV// Hib vaccine, Pentacel®

  • Pharmaceutical form:liquid Route of administration: oral

    Also known as: Rotavirus vaccine, RotaTeq

  • BiologicalHepatitis B Vaccine* [Recombinant] *as applicable

    Pharmaceutical form:liquid Route of administration: intramuscular

    Also known as: Hepatitis B vaccine, ENGERIX-B®

06

What researchers measure

Primary outcomes

  1. Number of Participants With Immediate Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant or in a clinical investigation participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. Immediate events were recorded to capture medically relevant unsolicited systemic AEs (including those related to the product administered) that occurred within the first 30 minutes after vaccination. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination and included both serious adverse events (SAEs) and non-serious unsolicited AEs.

    Time frame: Up to 30 minutes after each vaccination

  2. Number of Participants With Solicited Injection Site Reactions

    A solicited reaction was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted in the protocol and CRB and were considered to be related to the product administered. An injection site reaction was an adverse reaction at and around the injection site which were commonly inflammatory reactions. Solicited injection site reactions included tenderness, erythema and swelling around the injection site and were planned to be collected and reported for SP0202/Prevnar 13 for both toddlers and infants.

    Time frame: Up to 7 days after each vaccination

  3. Number of Participants With Solicited Systemic Reactions

    A solicited reaction was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB and considered as related to the product administered. Solicited systemic reactions included fever, vomiting, abnormal crying, drowsiness, appetite loss, and irritability. Reported AEs for each arm were presented as pre-specified in protocol.

    Time frame: Up to 7 days after each vaccination

  4. Number of Participants With Unsolicited AEs

    An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product, and which did not necessarily have a causal relationship with this treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRB in terms of diagnosis and/or onset window post-vaccination. Unsolicited AEs included both SAEs and non-serious unsolicited AEs. Reported AEs for each arm were presented as pre-specified in protocol.

    Time frame: Up to 30 days after each vaccination

  5. Number of Participants With SAEs and Adverse Event of Special Interest (AESIs)

    An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. The following AE were captured as AESI throughout the study: Anaphylaxis defined as per the Brighton collaboration case definition, convulsions including febrile convulsions, hypotonic-hyporesponsive episode and apnea. Reported AEs for each arm were presented as pre-specified in protocol.

    Time frame: From first dose vaccine administration (Day 1) until 6 months after the last dose administration, 490 days

  6. For Toddlers: Serotype Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each Pneumococcal Serotype at 30 Days Post-Dose

    The GMCs for serotype specific pneumococcal IgG antibodies were measured using pneumococcal capsular polysaccharide-electro-chemiluminescent assay (PnPS-ECL), a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.

    Time frame: Day 30

  7. For Infants: Percentage of Participants With Serotype Specific IgG Concentration >=0.35 mcg/mL 30 Days Post-Dose 3

    Percentage of infants with serotype specific IgG concentration \>=0.35 mcg/mL for each pneumococcal serotype included in the SP0202 formulations were measured using ECL, a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.

    Time frame: Day 150

  8. For Infants: Serotype Specific IgG GMCs for Each Pneumococcal Serotype at 30 Days Post-Dose 3

    The GMCs for serotype-specific pneumococcal IgG antibodies were measured using PnPS-ECL, a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.

    Time frame: Day 150

  9. For Infants: Serotype Specific IgG GMCs for Each Pneumococcal Serotype at 30 Days Post-Dose 4

    The GMCs for serotype specific pneumococcal IgG antibodies were measured using PnPS-ECL, a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.

    Time frame: Day 330

Secondary outcomes

  1. For Toddlers: Serotype Specific OPA Geometric Mean Titers (GMTs) for Each Pneumococcal Serotype 30 Days Post-Dose

    The GMs for serotype specific OPA titers were measured using multiplex opsonophagocytic assay (MOPA) which is used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination.

    Time frame: Day 30

  2. For Infants: Serotype Specific OPA GMTs for Each Pneumococcal Serotype 30 Days Post-Dose 3

    The GMs for serotype specific OPA titers were measured using MOPA which is used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination.

    Time frame: Day 150

  3. For Infants: Serotype Specific OPA GMTs for Each Pneumococcal Serotype 30 Days Post-Dose 4

    The GMs for serotype specific OPA titers were measured using MOPA which is used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination.

    Time frame: Day 330

  4. For Infants: GMC of Anti-Rotavirus Serum Immunoglobulin A (IgA) Antibodies 30 Days Post-Dose 3

    Anti-rotavirus IgA antibodies in human serum were measured by enzyme linked immunosorbent assay (ELISA). A reference standard assayed on each plate was used to calculate the amount of specific anti-rotavirus IgA antibody in the units assigned by the reference standard.

    Time frame: Day 150

  5. For Infants: Percentage of Participants With Antibody Responses to Diphtheria, Tetanus and Polyribosylribitol Phosphate Antigens 30 Days Post-Dose 3

    Percentage of participants with toxoid concentration \>=0.10 mcg/mL for diphtheria and tetanus and \>=0.15 mcg/mL for PRP are presented. Anti-diphtheria and anti-tetanus concentrations were measured using electro-chemiluminescence assay (ECL) and anti-PRP concentrations were measured using a Farr-type radioimmunoassay.

    Time frame: Day 150

  6. For Infants: Percentage of Participants With Antibody Responses to Poliovirus 1, 2 and 3 30 Days Post-Dose 3

    Anti-poliovirus types 1, 2, and 3 were measured by neutralization assay. Response was defined as a titer \>=8.

    Time frame: Day 150

  7. For Infants: GMCs of Antibodies to Pertussis Antigens 30 Days Post-Dose 3

    Serum samples were collected for analysis by ECL to determine the GMC of antibodies to the following Pertussis antigens: Pertussis toxoid/toxin, Filamentous hemagglutinin, Pertactin and Fimbriae types 2 and 3.

    Time frame: Day 150

  8. For Infants: Percentage of Participants With Antibody Responses to Hepatitis-B Antigens 30 Days Post-Dose 3

    Anti-Hepatitis B antibodies were measured by the commercially available VITROS ECi/ECiQ immunodiagnostic system using chemiluminescence detection technology. The VITROS ECi immunodiagnostic system uses an antibody mediated antigen sandwich formation to detect the presence of anti-hepatitis B surface antigen total immunoglobulin in human serum. The threshold presented is \>=10 milli international units (mIU).

    Time frame: Day 150

  9. For Infants: Percentage of Participants With Antibody Responses to M-MRII and Varivax Antigens 30 Days Post-Dose 4

    Anti-measles antibodies were determined by bulk measles IgG enzyme immunoassay (EIA); anti-mumps antibodies by ELISA, anti-rubella antibodies by bulk rubella IgG EIA and anti-varicella antibodies were determined by glycoprotein ELISA to detect total IgG antibody to respective virus before and after vaccination with a virus-containing vaccine. Percentage of participants with anti-measles antibody concentrations \>=255 mIU/mL, anti-mumps antibody concentrations: \>=10 antibody units/mL, anti-rubella antibody concentrations \>=10 IU/mL and anti-varicella concentrations \>=5 units/mL is reported in this outcome measure.

    Time frame: Day 330

07

Results

Posted Nov 12, 2024

Participant flow

The Stage I of study was conducted at 22 active centers in the US between 22 May 2020 and 10 March 2021. The Stage II of study was conducted at 35 active centers in the US, Canada and Honduras between 16 April 2021 and 24 February 2022.

Participant flow — Overall Study
MilestoneStage I: Group 1 SP0202-IIbStage I: Group 2 SP0202-VIStage I: Group 3 SP0202-VIIStage I: Group 4 Prevnar 13Stage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
Started35353535179178179176
Completed35313232148147151160
Not completed043331312816
Withdrew: Adverse event00000110
Withdrew: Lost to follow-up01216382
Withdrew: Withdrawal by parent/guardian021219231311
Withdrew: Protocol deviation01006463

Outcome measures

PrimaryNumber of Participants With Immediate Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant or in a clinical investigation participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. Immediate events were recorded to capture medically relevant unsolicited systemic AEs (including those related to the product administered) that occurred within the first 30 minutes after vaccination. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination and included both serious adverse events (SAEs) and non-serious unsolicited AEs.

Time frame:
Up to 30 minutes after each vaccination
Reported as:
Count of participants · Participants
Number of Participants With Immediate Adverse Events (AEs)
ParticipantsStage I: Group 1 SP0202-IIbStage I: Group 2 SP0202-VIStage I: Group 3 SP0202-VIIStage I: Group 4 Prevnar 13Stage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
Number of Participants With Immediate Adverse Events (AEs)00000000
PrimaryNumber of Participants With Solicited Injection Site Reactions

A solicited reaction was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted in the protocol and CRB and were considered to be related to the product administered. An injection site reaction was an adverse reaction at and around the injection site which were commonly inflammatory reactions. Solicited injection site reactions included tenderness, erythema and swelling around the injection site and were planned to be collected and reported for SP0202/Prevnar 13 for both toddlers and infants.

Time frame:
Up to 7 days after each vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Injection Site Reactions
ParticipantsStage I: Group 1 SP0202-IIbStage I: Group 2 SP0202-VIStage I: Group 3 SP0202-VIIStage I: Group 4 Prevnar 13Stage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
Number of Participants With Solicited Injection Site Reactions21182113119128126124
PrimaryNumber of Participants With Solicited Systemic Reactions

A solicited reaction was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB and considered as related to the product administered. Solicited systemic reactions included fever, vomiting, abnormal crying, drowsiness, appetite loss, and irritability. Reported AEs for each arm were presented as pre-specified in protocol.

Time frame:
Up to 7 days after each vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic Reactions
ParticipantsStage I: Group 1 SP0202-IIbStage I: Group 2 SP0202-VIStage I: Group 3 SP0202-VIIStage I: Group 4 Prevnar 13Stage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
Number of Participants With Solicited Systemic Reactions25232724139143137138
PrimaryNumber of Participants With Unsolicited AEs

An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product, and which did not necessarily have a causal relationship with this treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRB in terms of diagnosis and/or onset window post-vaccination. Unsolicited AEs included both SAEs and non-serious unsolicited AEs. Reported AEs for each arm were presented as pre-specified in protocol.

Time frame:
Up to 30 days after each vaccination
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited AEs
ParticipantsStage I: Group 1 SP0202-IIbStage I: Group 2 SP0202-VIStage I: Group 3 SP0202-VIIStage I: Group 4 Prevnar 13Stage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
Number of Participants With Unsolicited AEs7346122116118117
PrimaryNumber of Participants With SAEs and Adverse Event of Special Interest (AESIs)

An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. The following AE were captured as AESI throughout the study: Anaphylaxis defined as per the Brighton collaboration case definition, convulsions including febrile convulsions, hypotonic-hyporesponsive episode and apnea. Reported AEs for each arm were presented as pre-specified in protocol.

Time frame:
From first dose vaccine administration (Day 1) until 6 months after the last dose administration, 490 days
Reported as:
Count of participants · Participants
Number of Participants With SAEs and Adverse Event of Special Interest (AESIs)
ParticipantsStage I: Group 1 SP0202-IIbStage I: Group 2 SP0202-VIStage I: Group 3 SP0202-VIIStage I: Group 4 Prevnar 13Stage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
Any SAEs01003989
Any AESIs10001110
PrimaryFor Toddlers: Serotype Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each Pneumococcal Serotype at 30 Days Post-Dose

The GMCs for serotype specific pneumococcal IgG antibodies were measured using pneumococcal capsular polysaccharide-electro-chemiluminescent assay (PnPS-ECL), a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.

Time frame:
Day 30
Reported as:
Geometric mean · microgram/millilitre (mcg/mL)
For Toddlers: Serotype Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each Pneumococcal Serotype at 30 Days Post-Dose
microgram/millilitre (mcg/mL)Stage I: Group 1 SP0202-IIbStage I: Group 2 SP0202-VIStage I: Group 3 SP0202-VIIStage I: Group 4 Prevnar 13
Serotype 12.46 (1.59 to 3.82)2.12 (1.40 to 3.21)3.29 (2.55 to 4.24)3.80 (2.76 to 5.24)
Serotype 30.766 (0.569 to 1.03)0.973 (0.748 to 1.26)1.16 (0.963 to 1.40)0.835 (0.629 to 1.11)
Serotype 41.53 (1.07 to 2.19)1.51 (1.10 to 2.08)2.27 (1.58 to 3.27)1.73 (1.32 to 2.25)
Serotype 52.44 (1.74 to 3.42)2.38 (1.66 to 3.42)2.80 (2.00 to 3.93)2.69 (2.02 to 3.58)
Serotype 6A7.53 (5.48 to 10.4)5.87 (4.20 to 8.20)8.29 (6.51 to 10.6)8.54 (6.44 to 11.3)
Serotype 6B5.21 (3.67 to 7.40)4.16 (3.15 to 5.50)7.11 (5.21 to 9.70)5.77 (4.33 to 7.70)
Serotype 7F2.99 (2.32 to 3.86)3.23 (2.37 to 4.41)2.91 (2.23 to 3.80)3.80 (3.06 to 4.73)
Serotype 9V3.25 (2.47 to 4.27)2.99 (2.22 to 4.01)5.27 (3.99 to 6.97)3.13 (2.31 to 4.24)
Serotype 147.37 (5.39 to 10.1)6.54 (4.62 to 9.27)5.75 (4.48 to 7.38)9.83 (7.65 to 12.6)
Serotype 18C1.80 (1.25 to 2.59)2.23 (1.57 to 3.19)2.19 (1.67 to 2.87)2.53 (1.99 to 3.21)
Serotype 19A3.67 (2.56 to 5.26)5.41 (3.62 to 8.08)5.45 (4.17 to 7.11)6.20 (4.83 to 7.96)
Serotype 19F3.88 (2.77 to 5.42)4.12 (2.99 to 5.70)5.79 (4.02 to 8.35)6.50 (4.69 to 9.02)
Serotype 23F2.42 (1.71 to 3.43)2.65 (1.98 to 3.55)3.64 (2.75 to 4.82)3.02 (2.11 to 4.32)
Serotype 86.86 (4.96 to 9.50)4.91 (3.74 to 6.44)7.11 (5.17 to 9.80)0.235 (0.158 to 0.350)
Serotype 9N3.46 (2.21 to 5.43)2.02 (1.43 to 2.84)2.78 (2.04 to 3.79)0.668 (0.437 to 1.02)
Serotype 10A1.84 (1.18 to 2.87)1.05 (0.669 to 1.66)1.48 (0.988 to 2.21)0.244 (0.180 to 0.331)
Serotype 11A4.41 (3.25 to 5.99)3.20 (2.48 to 4.13)4.61 (3.34 to 6.35)0.188 (0.144 to 0.247)
Serotype 12F0.767 (0.454 to 1.29)0.778 (0.541 to 1.12)0.907 (0.596 to 1.38)0.094 (0.078 to 0.112)
Serotype 15B0.680 (0.447 to 1.03)0.560 (0.370 to 0.848)0.644 (0.425 to 0.974)0.172 (0.122 to 0.241)
Serotype 22F4.43 (3.12 to 6.30)4.26 (2.66 to 6.82)5.20 (3.51 to 7.69)0.178 (0.122 to 0.259)
Serotype 33F1.26 (0.694 to 2.29)1.13 (0.771 to 1.65)1.75 (1.09 to 2.79)0.256 (0.189 to 0.345)
PrimaryFor Infants: Percentage of Participants With Serotype Specific IgG Concentration >=0.35 mcg/mL 30 Days Post-Dose 3

Percentage of infants with serotype specific IgG concentration \>=0.35 mcg/mL for each pneumococcal serotype included in the SP0202 formulations were measured using ECL, a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.

Time frame:
Day 150
Reported as:
Number · percentage of participants
For Infants: Percentage of Participants With Serotype Specific IgG Concentration >=0.35 mcg/mL 30 Days Post-Dose 3
percentage of participantsStage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
Serotype 197.7 (93.5 to 99.5)96.7 (91.8 to 99.1)95.2 (89.8 to 98.2)97.0 (92.4 to 99.2)
Serotype 394.7 (89.5 to 97.9)95.1 (89.6 to 98.2)97.6 (93.1 to 99.5)81.8 (74.2 to 88.0)
Serotype 497.0 (92.5 to 99.2)95.9 (90.7 to 98.7)97.6 (93.1 to 99.5)97.7 (93.5 to 99.5)
Serotype 598.5 (94.7 to 99.8)96.7 (91.8 to 99.1)93.6 (87.8 to 97.2)97.0 (92.4 to 99.2)
Serotype 6A99.2 (95.9 to 100)96.7 (91.8 to 99.1)99.2 (95.6 to 100)99.2 (95.9 to 100)
Serotype 6B85.7 (78.6 to 91.2)81.1 (73.1 to 87.7)84.0 (76.4 to 89.9)97.0 (92.4 to 99.2)
Serotype 7F100 (97.3 to 100)100 (97.0 to 100)99.2 (95.6 to 100)100 (97.2 to 100)
Serotype 9V96.2 (91.4 to 98.8)89.3 (82.5 to 94.2)94.4 (88.8 to 97.7)99.2 (95.9 to 100)
Serotype 1499.2 (95.9 to 100)99.2 (95.5 to 100)97.6 (93.1 to 99.5)96.9 (92.4 to 99.2)
Serotype 18C97.0 (92.5 to 99.2)97.5 (93.0 to 99.5)97.6 (93.1 to 99.5)96.2 (91.4 to 98.8)
Serotype 19A94.0 (88.5 to 97.4)93.4 (87.5 to 97.1)96.0 (90.9 to 98.7)97.0 (92.4 to 99.2)
Serotype 19F100 (97.3 to 100)99.2 (95.5 to 100)96.8 (92.0 to 99.1)99.2 (95.8 to 100)
Serotype 23F97.7 (93.5 to 99.5)96.7 (91.8 to 99.1)96.0 (90.9 to 98.7)93.9 (88.4 to 97.3)
Serotype 899.2 (95.9 to 100)100 (97.0 to 100)99.2 (95.6 to 100)9.2 (4.8 to 15.5)
Serotype 9N99.2 (95.9 to 100)98.4 (94.2 to 99.8)98.4 (94.3 to 99.8)65.9 (57.2 to 73.9)
Serotype 10A93.2 (87.5 to 96.9)92.6 (86.5 to 96.6)96.0 (90.9 to 98.7)3.8 (1.2 to 8.6)
Serotype 11A98.5 (94.7 to 99.8)100 (97.0 to 100)97.6 (93.1 to 99.5)7.6 (3.7 to 13.5)
Serotype 12F97.7 (93.5 to 99.5)93.4 (87.5 to 97.1)94.4 (88.8 to 97.7)0 (0 to 2.8)
Serotype 15B98.5 (94.7 to 99.8)95.9 (90.7 to 98.7)97.6 (93.1 to 99.5)6.9 (3.2 to 12.6)
Serotype 22F100 (97.3 to 100)97.5 (93.0 to 99.5)97.6 (93.1 to 99.5)3.0 (0.8 to 7.6)
Serotype 33F91.7 (85.7 to 95.8)89.3 (82.5 to 94.2)92.8 (86.8 to 96.7)3.8 (1.3 to 8.7)
PrimaryFor Infants: Serotype Specific IgG GMCs for Each Pneumococcal Serotype at 30 Days Post-Dose 3

The GMCs for serotype-specific pneumococcal IgG antibodies were measured using PnPS-ECL, a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.

Time frame:
Day 150
Reported as:
Geometric mean · mcg/mL
For Infants: Serotype Specific IgG GMCs for Each Pneumococcal Serotype at 30 Days Post-Dose 3
mcg/mLStage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
Serotype 11.91 (1.66 to 2.19)2.21 (1.88 to 2.61)1.97 (1.66 to 2.34)2.81 (2.39 to 3.30)
Serotype 30.800 (0.721 to 0.887)1.14 (1.01 to 1.27)1.17 (1.04 to 1.31)0.676 (0.598 to 0.764)
Serotype 40.900 (0.819 to 0.988)0.880 (0.798 to 0.971)1.06 (0.951 to 1.18)1.63 (1.45 to 1.83)
Serotype 53.62 (3.02 to 4.35)3.26 (2.70 to 3.95)3.00 (2.42 to 3.71)1.88 (1.63 to 2.17)
Serotype 6A3.41 (2.93 to 3.96)2.77 (2.33 to 3.30)3.26 (2.78 to 3.82)4.53 (3.93 to 5.21)
Serotype 6B1.95 (1.52 to 2.49)1.64 (1.22 to 2.20)1.97 (1.51 to 2.59)2.87 (2.36 to 3.48)
Serotype 7F3.88 (3.47 to 4.34)3.68 (3.27 to 4.14)3.45 (3.05 to 3.90)3.93 (3.53 to 4.36)
Serotype 9V1.35 (1.18 to 1.55)1.16 (0.989 to 1.37)1.49 (1.27 to 1.74)2.41 (2.12 to 2.74)
Serotype 147.49 (6.36 to 8.81)6.83 (5.85 to 7.98)6.84 (5.73 to 8.17)7.41 (6.20 to 8.86)
Serotype 18C1.67 (1.49 to 1.87)1.56 (1.391 to 1.76)1.46 (1.31 to 1.63)1.92 (1.67 to 2.20)
Serotype 19A1.86 (1.57 to 2.20)1.74 (1.43 to 2.11)1.86 (1.57 to 2.21)2.17 (1.85 to 2.54)
Serotype 19F3.32 (2.98 to 3.70)3.31 (2.93 to 3.75)2.95 (2.51 to 3.46)3.70 (3.23 to 4.24)
Serotype 23F2.69 (2.31 to 3.13)1.96 (1.69 to 2.28)2.05 (1.73 to 2.43)1.71 (1.44 to 2.04)
Serotype 83.27 (2.92 to 3.66)2.87 (2.55 to 3.22)3.08 (2.70 to 3.51)0.105 (0.093 to 0.119)
Serotype 9N2.53 (2.26 to 2.84)2.39 (2.10 to 2.71)2.42 (2.12 to 2.77)0.510 (0.424 to 0.612)
Serotype 10A2.86 (2.29 to 3.57)2.84 (2.24 to 3.59)3.26 (2.68 to 3.97)0.098 (0.089 to 0.108)
Serotype 11A2.52 (2.21 to 2.88)2.51 (2.21 to 2.85)2.32 (1.99 to 2.71)0.108 (0.095 to 0.123)
Serotype 12F1.93 (1.68 to 2.23)1.56 (1.33 to 1.82)1.54 (1.31 to 1.81)0.076 (0.075 to 0.078)
Serotype 15B7.88 (6.54 to 9.48)7.161 (5.73 to 8.95)6.84 (5.54 to 8.45)0.097 (0.087 to 0.107)
Serotype 22F12.3 (10.8 to 14.1)10.4 (8.59 to 12.6)9.27 (7.58 to 11.3)0.092 (0.083 to 0.103)
Serotype 33F2.67 (2.11 to 3.37)2.61 (2.05 to 3.32)2.57 (2.09 to 3.16)0.093 (0.085 to 0.101)
PrimaryFor Infants: Serotype Specific IgG GMCs for Each Pneumococcal Serotype at 30 Days Post-Dose 4

The GMCs for serotype specific pneumococcal IgG antibodies were measured using PnPS-ECL, a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.

Time frame:
Day 330
Reported as:
Geometric mean · mcg/mL
For Infants: Serotype Specific IgG GMCs for Each Pneumococcal Serotype at 30 Days Post-Dose 4
mcg/mLStage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
Serotype 13.16 (2.68 to 3.73)3.59 (3.02 to 4.26)3.44 (2.87 to 4.12)3.89 (3.35 to 4.50)
Serotype 30.755 (0.675 to 0.844)1.07 (0.949 to 1.21)1.03 (0.922 to 1.16)0.961 (0.843 to 1.09)
Serotype 41.37 (1.18 to 1.59)1.25 (1.08 to 1.45)1.75 (1.49 to 2.05)2.41 (2.09 to 2.77)
Serotype 57.56 (6.24 to 9.18)6.46 (5.25 to 7.95)6.63 (5.32 to 8.24)3.07 (2.67 to 3.54)
Serotype 6A9.44 (8.01 to 11.1)8.08 (6.93 to 9.43)7.80 (6.50 to 9.36)10.8 (9.36 to 12.4)
Serotype 6B8.77 (7.14 to 10.8)8.36 (6.88 to 10.2)7.96 (6.63 to 9.57)8.54 (7.46 to 9.78)
Serotype 7F4.42 (3.93 to 4.97)4.19 (3.63 to 4.85)3.76 (3.33 to 4.24)5.41 (4.80 to 6.09)
Serotype 9V2.20 (1.89 to 2.57)2.06 (1.78 to 2.38)2.57 (2.20 to 3.01)4.32 (3.77 to 4.95)
Serotype 146.94 (5.93 to 8.11)6.77 (5.62 to 8.14)7.70 (6.58 to 9.00)8.73 (7.34 to 10.4)
Serotype 18C1.79 (1.58 to 2.02)1.66 (1.46 to 1.90)1.55 (1.37 to 1.77)2.81 (2.46 to 3.21)
Serotype 19A6.92 (5.79 to 8.28)7.36 (6.12 to 8.84)7.72 (6.37 to 9.36)7.38 (6.28 to 8.67)
Serotype 19F6.64 (5.75 to 7.67)7.48 (6.18 to 9.06)6.68 (5.62 to 7.94)7.03 (6.05 to 8.16)
Serotype 23F3.78 (3.19 to 4.49)2.90 (2.46 to 3.42)2.99 (2.50 to 3.57)3.54 (3.02 to 4.16)
Serotype 84.64 (3.94 to 5.46)4.36 (3.74 to 5.08)4.26 (3.56 to 5.10)0.238 (0.196 to 0.289)
Serotype 9N4.16 (3.60 to 4.79)4.23 (3.72 to 4.80)3.80 (3.18 to 4.54)0.953 (0.773 to 1.18)
Serotype 10A5.67 (4.71 to 6.83)5.70 (4.76 to 6.83)4.78 (3.96 to 5.78)0.160 (0.137 to 0.187)
Serotype 11A3.66 (3.17 to 4.21)3.92 (3.36 to 4.57)3.22 (2.69 to 3.85)0.154 (0.128 to 0.186)
Serotype 12F2.68 (2.30 to 3.13)2.25 (1.94 to 2.61)2.04 (1.73 to 2.41)0.080 (0.076 to 0.085)
Serotype 15B19.6 (16.5 to 23.2)17.3 (14.2 to 21.2)15.7 (12.6 to 19.5)0.114 (0.097 to 0.134)
Serotype 22F24.5 (21.1 to 28.3)21.3 (17.8 to 25.6)20.6 (16.8 to 25.2)0.173 (0.144 to 0.206)
Serotype 33F4.74 (4.07 to 5.52)4.83 (4.13 to 5.65)4.62 (3.89 to 5.49)0.158 (0.134 to 0.186)
SecondaryFor Toddlers: Serotype Specific OPA Geometric Mean Titers (GMTs) for Each Pneumococcal Serotype 30 Days Post-Dose

The GMs for serotype specific OPA titers were measured using multiplex opsonophagocytic assay (MOPA) which is used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination.

Time frame:
Day 30
Reported as:
Geometric mean · 1/dilution (1/dil)
For Toddlers: Serotype Specific OPA Geometric Mean Titers (GMTs) for Each Pneumococcal Serotype 30 Days Post-Dose
1/dilution (1/dil)Stage I: Group 1 SP0202-IIbStage I: Group 2 SP0202-VIStage I: Group 3 SP0202-VIIStage I: Group 4 Prevnar 13
Serotype 1138 (62.1 to 306)94.2 (49.9 to 178)177 (92.3 to 339)247 (140 to 434)
Serotype 3272 (204 to 363)314 (229 to 431)393 (287 to 537)216 (160 to 292)
Serotype 43467 (2296 to 5234)2862 (2027 to 4041)5420 (3366 to 8725)2975 (1981 to 4466)
Serotype 51287 (736 to 2252)1333 (867 to 2050)1397 (817 to 2389)1307 (820 to 2082)
Serotype 6A4623 (3110 to 6871)6083 (4341 to 8523)7232 (5071 to 10315)7553 (5386 to 10592)
Serotype 6B3027 (1935 to 4737)3542 (2348 to 5342)5171 (3369 to 7935)4679 (3132 to 6992)
Serotype 7F8449 (5127 to 13924)7640 (4974 to 11734)6284 (4099 to 9634)10443 (6580 to 16575)
Serotype 9V3612 (2492 to 5236)3254 (2121 to 4991)4720 (2911 to 7654)4057 (2778 to 5926)
Serotype 143598 (2195 to 5898)3881 (2534 to 5943)3191 (2045 to 4979)2828 (1948 to 4107)
Serotype 18C1490 (921 to 2411)1760 (1176 to 2634)1722 (1233 to 2404)2424 (1558 to 3771)
Serotype 19A3082 (2115 to 4493)3174 (2302 to 4377)3004 (2121 to 4256)5354 (3343 to 8577)
Serotype 19F1194 (838 to 1701)1806 (1207 to 2702)1569 (955 to 2576)2554 (1818 to 3588)
Serotype 23F5451 (3431 to 8662)7457 (5131 to 10838)5179 (3303 to 8121)9264 (5738 to 14957)
Serotype 84244 (2705 to 6658)7003 (5065 to 9681)7989 (5076 to 12576)222 (120 to 412)
Serotype 9N11562 (9510 to 14057)8391 (6117 to 11511)12115 (8129 to 18054)2061 (1445 to 2940)
Serotype 10A3582 (2518 to 5096)3615 (2706 to 4829)4001 (2768 to 5782)10.0 (4.07 to 24.7)
Serotype 11A611 (378 to 988)686 (349 to 1345)661 (311 to 1408)4.14 (3.86 to 4.44)
Serotype 12F6767 (4628 to 9895)7391 (4704 to 11615)7955 (4793 to 13205)5.27 (3.28 to 8.46)
Serotype 15B1087 (402 to 2941)1346 (496 to 3658)1476 (467 to 4671)37.7 (20.3 to 69.8)
Serotype 22F4106 (2963 to 5690)3352 (2354 to 4773)4443 (2858 to 6906)69.0 (24.3 to 196)
Serotype 33F39691 (27999 to 56266)30399 (18394 to 50238)35326 (24106 to 51770)2689 (1702 to 4249)
SecondaryFor Infants: Serotype Specific OPA GMTs for Each Pneumococcal Serotype 30 Days Post-Dose 3

The GMs for serotype specific OPA titers were measured using MOPA which is used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination.

Time frame:
Day 150
Reported as:
Geometric mean · 1/dil
For Infants: Serotype Specific OPA GMTs for Each Pneumococcal Serotype 30 Days Post-Dose 3
1/dilStage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
Serotype 173.6 (53.4 to 101)81.7 (59.1 to 113)66.4 (46.7 to 94.5)114 (86.4 to 151)
Serotype 3170 (146 to 197)218 (180 to 266)260 (226 to 300)178 (147 to 215)
Serotype 4703 (586 to 843)616 (492 to 771)1154 (934 to 1425)1789 (1489 to 2151)
Serotype 5602 (469 to 771)492 (372 to 652)495 (370 to 662)569 (450 to 719)
Serotype 6A2456 (2032 to 2969)2223 (1743 to 2834)2664 (2187 to 3245)2799 (2307 to 3395)
Serotype 6B1436 (1008 to 2045)1041 (677 to 1602)1885 (1384 to 2567)2472 (1934 to 3160)
Serotype 7F5964 (4989 to 7130)5449 (4536 to 6545)5889 (4980 to 6963)5252 (4521 to 6102)
Serotype 9V898 (659 to 1224)700 (483 to 1014)1136 (866 to 1492)1319 (1040 to 1672)
Serotype 141959 (1580 to 2429)1767 (1391 to 2244)2293 (1858 to 2829)1920 (1574 to 2344)
Serotype 18C866 (731 to 1026)819 (668 to 1003)804 (660 to 979)1000 (804 to 1245)
Serotype 19A640 (521 to 788)512 (384 to 684)778 (630 to 962)1130 (959 to 1332)
Serotype 19F533 (422 to 674)591 (451 to 774)629 (461 to 860)613 (489 to 768)
Serotype 23F2654 (2157 to 3265)1967 (1500 to 2580)2279 (1770 to 2934)4299 (3536 to 5227)
Serotype 81486 (1239 to 1782)1440 (1237 to 1677)1612 (1378 to 1886)133 (89.9 to 196)
Serotype 9N4261 (3534 to 5138)4994 (4248 to 5870)5257 (4150 to 6661)811 (585 to 1126)
Serotype 10A2306 (1539 to 3453)2722 (1875 to 3951)3251 (2501 to 4225)9.42 (6.33 to 14.0)
Serotype 11A52.6 (36.7 to 75.3)64.9 (44.2 to 95.3)76.6 (52.6 to 112)5.91 (4.62 to 7.54)
Serotype 12F2182 (1764 to 2700)2179 (1798 to 2640)2334 (1836 to 2967)5.31 (4.15 to 6.80)
Serotype 15B6686 (5281 to 8466)5859 (4218 to 8139)5220 (3829 to 7116)28.1 (22.8 to 34.7)
Serotype 22F5227 (4421 to 6181)4657 (3802 to 5706)4617 (3725 to 5723)16.1 (12.5 to 20.7)
Serotype 33F10070 (7198 to 14088)11179 (8604 to 14524)11900 (8552 to 16559)311 (181 to 535)
SecondaryFor Infants: Serotype Specific OPA GMTs for Each Pneumococcal Serotype 30 Days Post-Dose 4

The GMs for serotype specific OPA titers were measured using MOPA which is used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination.

Time frame:
Day 330
Reported as:
Geometric mean · 1/dil
For Infants: Serotype Specific OPA GMTs for Each Pneumococcal Serotype 30 Days Post-Dose 4
1/dilStage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
Serotype 1407 (295 to 561)355 (255 to 495)320 (211 to 486)318 (251 to 403)
Serotype 3274 (230 to 328)308 (244 to 390)376 (314 to 450)348 (294 to 412)
Serotype 43754 (3002 to 4694)2536 (1915 to 3359)5556 (4318 to 7150)6028 (4801 to 7570)
Serotype 52348 (1884 to 2926)1787 (1365 to 2339)2131 (1626 to 2794)1396 (1119 to 1740)
Serotype 6A5153 (4338 to 6119)4786 (3929 to 5829)4433 (3434 to 5722)6862 (5741 to 8202)
Serotype 6B3899 (3019 to 5037)3305 (2614 to 4178)3638 (2756 to 4802)7092 (5699 to 8825)
Serotype 7F10234 (8469 to 12368)8643 (7263 to 10285)9232 (7448 to 11444)13971 (11575 to 16863)
Serotype 9V3044 (2424 to 3823)2641 (2137 to 3263)2956 (2363 to 3698)4364 (3459 to 5505)
Serotype 143415 (2785 to 4188)3098 (2527 to 3798)4190 (3397 to 5168)3378 (2559 to 4459)
Serotype 18C1891 (1565 to 2285)1422 (1110 to 1823)1368 (1092 to 1713)2821 (2342 to 3399)
Serotype 19A3808 (3057 to 4743)3086 (2422 to 3933)3580 (2806 to 4566)7535 (6068 to 9357)
Serotype 19F2071 (1730 to 2481)1821 (1313 to 2527)1654 (1173 to 2332)2249 (1750 to 2889)
Serotype 23F5444 (4211 to 7037)4444 (3644 to 5418)4047 (3019 to 5424)18569 (14765 to 23352)
Serotype 84559 (3753 to 5537)4229 (3527 to 5070)4916 (3751 to 6443)773 (616 to 970)
Serotype 9N9479 (7967 to 11277)8565 (7485 to 9800)10257 (8771 to 11995)3043 (2370 to 3906)
Serotype 10A4278 (3125 to 5856)4797 (3722 to 6184)4768 (3358 to 6770)46.6 (23.9 to 90.9)
Serotype 11A433 (310 to 604)390 (253 to 603)550 (372 to 812)8.11 (5.45 to 12.1)
Serotype 12F4520 (3743 to 5459)4757 (3800 to 5956)5030 (3785 to 6685)7.92 (5.26 to 12.0)
Serotype 15B14756 (11612 to 18750)13136 (9623 to 17932)12799 (9111 to 17981)55.2 (36.7 to 83.0)
Serotype 22F20372 (15640 to 26536)16063 (12306 to 20967)21319 (15648 to 29045)65.7 (37.7 to 114)
Serotype 33F26134 (20845 to 32766)21202 (17071 to 26332)32376 (25782 to 40657)3224 (2388 to 4353)
SecondaryFor Infants: GMC of Anti-Rotavirus Serum Immunoglobulin A (IgA) Antibodies 30 Days Post-Dose 3

Anti-rotavirus IgA antibodies in human serum were measured by enzyme linked immunosorbent assay (ELISA). A reference standard assayed on each plate was used to calculate the amount of specific anti-rotavirus IgA antibody in the units assigned by the reference standard.

Time frame:
Day 150
Reported as:
Geometric mean · Units (U)/mL
For Infants: GMC of Anti-Rotavirus Serum Immunoglobulin A (IgA) Antibodies 30 Days Post-Dose 3
Units (U)/mLStage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
For Infants: GMC of Anti-Rotavirus Serum Immunoglobulin A (IgA) Antibodies 30 Days Post-Dose 3407 (303 to 545)390 (283 to 537)494 (369 to 661)393 (277 to 560)
SecondaryFor Infants: Percentage of Participants With Antibody Responses to Diphtheria, Tetanus and Polyribosylribitol Phosphate Antigens 30 Days Post-Dose 3

Percentage of participants with toxoid concentration \>=0.10 mcg/mL for diphtheria and tetanus and \>=0.15 mcg/mL for PRP are presented. Anti-diphtheria and anti-tetanus concentrations were measured using electro-chemiluminescence assay (ECL) and anti-PRP concentrations were measured using a Farr-type radioimmunoassay.

Time frame:
Day 150
Reported as:
Number · percentage of participants
For Infants: Percentage of Participants With Antibody Responses to Diphtheria, Tetanus and Polyribosylribitol Phosphate Antigens 30 Days Post-Dose 3
percentage of participantsStage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
Anti-Diphtheria toxoid94.6 (89.2 to 97.8)97.5 (92.7 to 99.5)95.9 (90.8 to 98.7)96.9 (92.3 to 99.2)
Anti-Tetanus toxoid100 (97.2 to 100)100 (96.9 to 100)100 (97.0 to 100)100 (97.2 to 100)
Anti-PRP99.2 (95.7 to 100)99.1 (95.2 to 100)98.2 (93.7 to 99.8)100 (97.2 to 100)
SecondaryFor Infants: Percentage of Participants With Antibody Responses to Poliovirus 1, 2 and 3 30 Days Post-Dose 3

Anti-poliovirus types 1, 2, and 3 were measured by neutralization assay. Response was defined as a titer \>=8.

Time frame:
Day 150
Reported as:
Number · percentage of participants
For Infants: Percentage of Participants With Antibody Responses to Poliovirus 1, 2 and 3 30 Days Post-Dose 3
percentage of participantsStage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
Anti-poliovirus 199.2 (95.6 to 100)100 (96.7 to 100)97.4 (92.5 to 99.5)100 (97.1 to 100)
Anti-poliovirus 2100 (97.0 to 100)100 (96.5 to 100)99.1 (95.1 to 100)100 (97.1 to 100)
Anti-poliovirus 3100 (97.1 to 100)100 (96.7 to 100)99.1 (95.1 to 100)100 (97.1 to 100)
SecondaryFor Infants: GMCs of Antibodies to Pertussis Antigens 30 Days Post-Dose 3

Serum samples were collected for analysis by ECL to determine the GMC of antibodies to the following Pertussis antigens: Pertussis toxoid/toxin, Filamentous hemagglutinin, Pertactin and Fimbriae types 2 and 3.

Time frame:
Day 150
Reported as:
Geometric mean · ELISA units (EU)/mL
For Infants: GMCs of Antibodies to Pertussis Antigens 30 Days Post-Dose 3
ELISA units (EU)/mLStage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
Pertussis toxoid/toxin67.9 (60.1 to 76.6)77.2 (67.4 to 88.5)66.3 (57.4 to 76.6)68.3 (59.7 to 78.2)
Filamentous hemagglutinin109 (94.9 to 124)107 (94.4 to 122)108 (95.2 to 123)104 (93.0 to 116)
Pertactin38.3 (32.3 to 45.4)36.1 (29.4 to 44.3)39.8 (32.8 to 48.3)45.2 (37.7 to 54.1)
Fimbriae types 2 and 3347 (295 to 408)341 (286 to 407)315 (262 to 380)343 (282 to 418)
SecondaryFor Infants: Percentage of Participants With Antibody Responses to Hepatitis-B Antigens 30 Days Post-Dose 3

Anti-Hepatitis B antibodies were measured by the commercially available VITROS ECi/ECiQ immunodiagnostic system using chemiluminescence detection technology. The VITROS ECi immunodiagnostic system uses an antibody mediated antigen sandwich formation to detect the presence of anti-hepatitis B surface antigen total immunoglobulin in human serum. The threshold presented is \>=10 milli international units (mIU).

Time frame:
Day 150
Reported as:
Number · percentage of participants
For Infants: Percentage of Participants With Antibody Responses to Hepatitis-B Antigens 30 Days Post-Dose 3
percentage of participantsStage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
For Infants: Percentage of Participants With Antibody Responses to Hepatitis-B Antigens 30 Days Post-Dose 398.3 (94.2 to 99.8)99.1 (94.9 to 100)98.1 (93.5 to 99.8)99.2 (95.6 to 100)
SecondaryFor Infants: Percentage of Participants With Antibody Responses to M-MRII and Varivax Antigens 30 Days Post-Dose 4

Anti-measles antibodies were determined by bulk measles IgG enzyme immunoassay (EIA); anti-mumps antibodies by ELISA, anti-rubella antibodies by bulk rubella IgG EIA and anti-varicella antibodies were determined by glycoprotein ELISA to detect total IgG antibody to respective virus before and after vaccination with a virus-containing vaccine. Percentage of participants with anti-measles antibody concentrations \>=255 mIU/mL, anti-mumps antibody concentrations: \>=10 antibody units/mL, anti-rubella antibody concentrations \>=10 IU/mL and anti-varicella concentrations \>=5 units/mL is reported in this outcome measure.

Time frame:
Day 330
Reported as:
Number · percentage of participants
For Infants: Percentage of Participants With Antibody Responses to M-MRII and Varivax Antigens 30 Days Post-Dose 4
percentage of participantsStage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
Anti-Measles97.5 (92.7 to 99.5)97.1 (91.8 to 99.4)96.9 (91.3 to 99.4)98.4 (94.3 to 99.8)
Anti-Mumps99.2 (95.4 to 100)97.1 (91.8 to 99.4)96.9 (91.3 to 99.4)98.4 (94.3 to 99.8)
Anti-Rubella98.3 (94.0 to 99.8)98.1 (93.2 to 99.8)99.0 (94.4 to 100)98.4 (94.3 to 99.8)
Anti-Varicella100 (96.9 to 100)99.0 (94.8 to 100)95.9 (89.9 to 98.9)98.4 (94.3 to 99.8)

Adverse events

Collected over AEs data was collected from first dose vaccine administration (Day 1) until 6 months after the last dose administration, 490 days. All-cause mortality was collected up to end of the study (Stage I: 6 months and Stage II: 19 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stage I: Group 1 SP0202-IIb0/35 (0%)0/35 (0%)28/35 (80%)
Stage I: Group 2 SP0202-VI0/34 (0%)1/34 (2.9%)28/34 (82.4%)
Stage I: Group 3 SP0202-VII0/35 (0%)0/35 (0%)29/35 (82.9%)
Stage I: Group 4 Prevnar 130/34 (0%)0/34 (0%)25/34 (73.5%)
Stage II: Group 5 SP0202-IIb0/180 (0%)3/180 (1.7%)160/180 (88.9%)
Stage II: Group 6 SP0202-VI1/178 (0.6%)9/178 (5.1%)164/178 (92.1%)
Stage II: Group 7 SP0202-VII0/176 (0%)8/176 (4.5%)159/176 (90.3%)
Stage II: Group 8 Prevnar 130/176 (0%)9/176 (5.1%)158/176 (89.8%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventStage I: Group 1 SP0202-IIbStage I: Group 2 SP0202-VIStage I: Group 3 SP0202-VIIStage I: Group 4 Prevnar 13Stage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
Hand-Foot-And-Mouth DiseaseInfections and infestations0/351/340/350/340/1800/1780/1760/176
PneumoniaInfections and infestations0/350/340/350/341/1800/1781/1762/176
Respiratory Syncytial Virus BronchiolitisInfections and infestations0/350/340/350/340/1802/1781/1760/176
Eyelid PtosisEye disorders0/350/340/350/340/1800/1781/1760/176
HaematocheziaGastrointestinal disorders0/350/340/350/340/1800/1780/1761/176
BronchiolitisInfections and infestations0/350/340/350/340/1801/1780/1761/176
Covid-19Infections and infestations0/350/340/350/340/1800/1780/1761/176
GastroenteritisInfections and infestations0/350/340/350/340/1801/1780/1761/176
Pneumonia InfluenzalInfections and infestations0/350/340/350/340/1800/1781/1760/176
PyelonephritisInfections and infestations0/350/340/350/340/1801/1781/1760/176
Most frequent other events
Showing 10 of 17
Most frequent other events
EventStage I: Group 1 SP0202-IIbStage I: Group 2 SP0202-VIStage I: Group 3 SP0202-VIIStage I: Group 4 Prevnar 13Stage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13
Injection Site PainGeneral disorders16/3512/3419/3513/34120/180127/178125/176124/176
IrritabilityPsychiatric disorders21/3516/3422/3520/34110/180116/178114/176117/176
CryingGeneral disorders16/356/3417/3517/34113/180112/178101/176106/176
SomnolenceNervous system disorders12/3511/3412/3510/3494/18097/17892/176104/176
Injection Site ErythemaGeneral disorders20/3514/3413/3510/3471/18058/17865/17665/176
Injection Site SwellingGeneral disorders16/3514/3414/359/3450/18048/17849/17659/176
Decreased AppetiteMetabolism and nutrition disorders9/357/3413/3511/3470/18070/17868/17667/176
PyrexiaGeneral disorders4/357/348/359/3467/18061/17863/17668/176
NasopharyngitisInfections and infestations1/351/340/350/3461/18055/17861/17648/176
VomitingGastrointestinal disorders3/350/342/353/3443/18036/17843/17645/176

Baseline characteristics

Age, Continuous
Age, Continuous(years)Stage I: Group 1 SP0202-IIbStage I: Group 2 SP0202-VIStage I: Group 3 SP0202-VIIStage I: Group 4 Prevnar 13Stage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13Total
Mean1.1 ± 0.111.1 ± 0.101.1 ± 0.121.2 ± 0.110.2 ± 0.030.2 ± 0.030.2 ± 0.030.2 ± 0.030.3 ± 0.36
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Stage I: Group 1 SP0202-IIbStage I: Group 2 SP0202-VIStage I: Group 3 SP0202-VIIStage I: Group 4 Prevnar 13Stage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13Total
Female1712201793947890421
Male18221518868410186430
Missing010000001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Stage I: Group 1 SP0202-IIbStage I: Group 2 SP0202-VIStage I: Group 3 SP0202-VIIStage I: Group 4 Prevnar 13Stage II: Group 5 SP0202-IIbStage II: Group 6 SP0202-VIStage II: Group 7 SP0202-VIIStage II: Group 8 Prevnar 13Total
American Indian or Alaska Native210226262323103
Asian102210028
Black or African American52361017101164
Native Hawaiian or Other Pacific Islander100000001
White2428292575677980407
Multiple230064676759262
Not Reported001020014
Unknown000011002
Missing010000001
08

Study locations

57 sites
  • The Children's Clinic Of Jonesboro PA Site Number : 8400143
    Jonesboro, Arkansas 72401, United States
  • Southland Clinical Research Center Site Number : 8400040
    Bellflower, California 90706, United States
  • Joint Clinical Trials Huntington Park Site Number : 8400030
    Huntington Park, California 90255, United States
  • Matrix Clinical Research Huntington Park Site Number : 8400058
    Huntington Park, California 90255, United States
  • Matrix Clinical Research Site Number : 8400059
    Los Angeles, California 90057, United States
  • Orange County Research Institute Site Number : 8400060
    Ontario, California 91762, United States
  • California Research Foundation Site Number : 8400052
    San Diego, California 92123-1881, United States
  • Meridian Clinical Research Washington DC Site Number : 8400119
    Washington D.C., District of Columbia 20016, United States
  • International Research Partners, LLC Site Number : 8400077
    Doral, Florida 33122, United States
  • Homestead Medical Clinic, P.A. Site Number : 8400032
    Homestead, Florida 33030, United States
  • Dade Research Center Site Number : 8400122
    Miami, Florida 33135, United States
  • Miami Clinical Research Site Number : 8400020
    Miami, Florida 33155, United States
  • Amber Clinical Research, LLC Site Number : 8400019
    Miami, Florida 33164, United States
  • Jedidiah Clinical Research Site Number : 8400049
    Tampa, Florida 33617, United States
  • Javara Albany Site Number : 8400140
    Albany, Georgia 31707, United States
  • Centricity Research Talbotton - DBA IACT Health Research at Talbotton Site Number : 8400062
    Columbus, Georgia 31904, United States
  • Javara Fayetteville Site Number : 8400139
    Fayetteville, Georgia 30214, United States
  • Dumog Research Site Number : 8400134
    Smyrna, Georgia 30080, United States
  • Bingham Memorial Hospital Site Number : 8400067
    Blackfoot, Idaho 83221, United States
  • Leavitt Clinical Research Site Number : 8400127
    Idaho Falls, Idaho 83404, United States
  • Hutchinson Clinic Site Number : 8400074
    Hutchinson, Kansas 67502, United States
  • Qualmedica Research, LLC Site Number : 8400084
    Bowling Green, Kentucky 42101, United States
  • Michael W. Simon, MD, PSC Site Number : 8400002
    Lexington, Kentucky 40517, United States
  • Meridian Clinical Research, LLC Site Number : 8400112
    Baton Rouge, Louisiana 70806, United States
  • Benchmark Research Site Number : 8400012
    Covington, Louisiana 70433, United States
  • Velocity Clinical Research Lafayette Site Number : 8400132
    Lafayette, Louisiana 70508, United States
  • Javara Annapolis Site Number : 8400137
    Annapolis, Maryland 21401, United States
  • Javara Chevy Chase Site Number : 8400138
    Chevy Chase, Maryland 20815, United States
  • Children's Mercy Hospital Site Number : 8400008
    Kansas City, Missouri 64108, United States
  • Boeson Research Site Number : 8400004
    Missoula, Montana 59804, United States
  • Meridian Clinical Research Site Number : 8400102
    Grand Island, Nebraska 68803, United States
  • Lincoln Pediatric Group Site Number : 8400125
    Lincoln, Nebraska 68516, United States
  • Pediatric Infectious Diseases Research Site Number : 8400104
    Omaha, Nebraska 68131, United States
  • Atrium Health Site Number : 8400124
    Charlotte, North Carolina 28204, United States
  • Ardmore Medical Research Site Number : 8400043
    Winston-Salem, North Carolina 27103, United States
  • Pediatric Associates of Mt. Carmel Site Number : 8400005
    Cincinnati, Ohio 45245, United States
  • Cheraw Pediatrics Site Number : 8400017
    Cheraw, South Carolina 29520, United States
  • Tribe Clinical Research Site Number : 8400025
    Greenville, South Carolina 29607, United States
  • Javara Dallas Site Number : 8400135
    Dallas, Texas 75230, United States
  • Pininos Pediatric Services Site Number : 8400121
    El Paso, Texas 79902, United States
  • North Texas Clinical Trials Site Number : 8400015
    Fort Worth, Texas 76104, United States
  • Houston Clinical Research Associates Site Number : 8400023
    Houston, Texas 77090, United States
  • FMC Science, LLC Site Number : 8400086
    Lampasas, Texas 76550-1820, United States
  • DCOL Center for Clinical Research Site Number : 8400107
    Longview, Texas 75605, United States
  • Biopharma Informatic Site Number : 8400066
    McAllen, Texas 78503, United States
  • Benchmark Research San Antonio Site Number : 8400129
    San Antonio, Texas 78201, United States
  • Sun Research Institute Site Number : 8400011
    San Antonio, Texas 78205, United States
  • Tekton Research Site Number : 8400076
    San Antonio, Texas 78244, United States
  • MultiCare Institute for Research & Innovation Site Number : 8400024
    Spokane, Washington 99202, United States
  • Investigational Site Number : 1240002
    Vancouver, British Columbia V5Z4H4, Canada
  • Investigational Site Number : 1240001
    Halifax, Nova Scotia B3K6R8, Canada
  • Investigational Site Number : 1240006
    Hamilton, Ontario L8M 1K7, Canada
  • Investigational Site Number : 3400002
    Municipio Del Distrito Central, 11101, Honduras
  • Investigational Site Number : 3400001
    San Pedro Sula, 21104, Honduras
  • Investigational Site Number : 6300002
    Bayamón, 00961, Puerto Rico
  • Investigational Site Number : 6300004
    Guayama, 000784, Puerto Rico
  • Investigational Site Number : 6300001
    San Juan, 00935, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Aug 2023, 38 months.

Results were first posted in Nov 2024, 1 year 3 months after primary completion.

Of 17 phase 2 interventional studies under Chickenpox, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 38. This study's 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2020
First posted
May 21, 2020
StartActual
May 22, 2020
Primary completionActual
Aug 10, 2023
CompletionActual
Aug 10, 2023
Results first posted
Nov 12, 2024
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04398706
Responsible party
Sponsor
First posted
May 21, 2020
Start date
May 22, 2020
Primary completion
Aug 10, 2023
Completion
Aug 10, 2023
Results posted
Nov 12, 2024
Last update
Sep 8, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi Pasteur, a Sanofi Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Chickenpox Vaccine · RotaTeq

Start the discussion